Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements
Aditxt (NASDAQ: ADTX) has successfully regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2). As a result, the previously scheduled hearing before the Hearings Panel for April 22, 2025, has been cancelled. The company will continue trading on the Nasdaq Capital Market under the symbol ADTX.
The social innovation platform, focused on accelerating promising health innovations in areas including autoimmunity and cancer, received official notification from the Nasdaq Stock Market's Listing Qualifications Department confirming their compliance status.
Aditxt (NASDAQ: ADTX) ha ripristinato con successo la conformità ai requisiti di prezzo minimo delle offerte di Nasdaq secondo la Regola di Quotazione 5550(a)(2). Di conseguenza, l'udienza precedentemente programmata davanti al Comitato delle Udienze per il 22 aprile 2025 è stata annullata. La società continuerà a essere quotata sul Nasdaq Capital Market con il simbolo ADTX.
La piattaforma di innovazione sociale, focalizzata sull'accelerazione di promettenti innovazioni sanitarie in settori come l'autoimmunità e il cancro, ha ricevuto notifica ufficiale dal Dipartimento delle Qualifiche di Quotazione del Nasdaq Stock Market che conferma il loro stato di conformità.
Aditxt (NASDAQ: ADTX) ha recuperado con éxito el cumplimiento del requisito de precio mínimo de oferta de Nasdaq bajo la Regla de Cotización 5550(a)(2). Como resultado, la audiencia previamente programada ante el Panel de Audiencias para el 22 de abril de 2025 ha sido cancelada. La empresa continuará cotizando en el Nasdaq Capital Market bajo el símbolo ADTX.
La plataforma de innovación social, centrada en acelerar innovaciones en salud prometedoras en áreas como la autoinmunidad y el cáncer, recibió notificación oficial del Departamento de Calificaciones de Cotización del Nasdaq Stock Market confirmando su estado de cumplimiento.
Aditxt (NASDAQ: ADTX)는 나스닥의 최소 입찰 가격 요구 사항을 제5550(a)(2) 규정에 따라 성공적으로 회복했습니다. 그 결과, 2025년 4월 22일로 예정된 청문회가 취소되었습니다. 회사는 Nasdaq Capital Market에서 ADTX라는 기호로 계속 거래될 것입니다.
자가면역 및 암을 포함한 분야에서 유망한 건강 혁신을 가속화하는 데 중점을 둔 사회 혁신 플랫폼은 나스닥 주식 시장의 상장 자격 부서로부터 그들의 준수 상태를 확인하는 공식 통지를 받았습니다.
Aditxt (NASDAQ: ADTX) a réussi à retrouver sa conformité avec l'exigence de prix d'offre minimum de Nasdaq selon la Règle de Cotation 5550(a)(2). En conséquence, l'audience précédemment prévue devant le Panel des Audiences pour le 22 avril 2025 a été annulée. La société continuera à être cotée sur le Nasdaq Capital Market sous le symbole ADTX.
La plateforme d'innovation sociale, axée sur l'accélération des innovations en santé prometteuses dans des domaines tels que l'auto-immunité et le cancer, a reçu une notification officielle du Département des Qualifications de Cotation de la Bourse Nasdaq confirmant leur statut de conformité.
Aditxt (NASDAQ: ADTX) hat erfolgreich die Einhaltung der Mindestgebotsanforderungen von Nasdaq gemäß dem Listungsregelwerk 5550(a)(2) wiederhergestellt. Infolgedessen wurde die zuvor für den 22. April 2025 anberaumte Anhörung vor dem Anhörungsgremium abgesagt. Das Unternehmen wird weiterhin unter dem Symbol ADTX am Nasdaq Capital Market gehandelt.
Die soziale Innovationsplattform, die sich auf die Beschleunigung vielversprechender Gesundheitsinnovationen in Bereichen wie Autoimmunität und Krebs konzentriert, erhielt eine offizielle Mitteilung von der Abteilung für Listungsqualifikationen der Nasdaq Stock Market, die ihren Compliance-Status bestätigt.
- Regained Nasdaq listing compliance, eliminating delisting risk
- Maintains Nasdaq Capital Market visibility and trading status
- None.
“We are pleased to have regained compliance with Nasdaq’s listing requirements. We continue to remain focused on advancing our progress towards addressing autoimmunity, cancer, and other pressing health challenges,” said Amro Albanna, Co-founder and CEO of Aditxt.
About Aditxt
Aditxt, Inc.® is a social innovation platform dedicated to accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that socializes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress.
For more information, www.aditxt.com.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of federal securities laws. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ongoing and planned product and business development; the Company’s ability to finance and execute its strategic M&A initiatives; the Company’s ability to obtain the necessary funding and partner to commence clinical trials; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth, and strategies; the Company’s ability to raise additional capital; expected usage of the Company’s ELOC and ATM facilities; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as market and other conditions and those risks more fully discussed in the section titled "Risk Factors" in Aditxt’s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250409695793/en/
Corporate Communications
Jeff Ramson, PCG Advisory
T: 646-863-6893
jramson@pcgadvisory.com
Source: Aditxt, Inc.
FAQ
What does Aditxt's (ADTX) Nasdaq compliance mean for investors?
Which Nasdaq requirement did ADTX regain compliance with in 2025?
Was ADTX's scheduled Nasdaq hearing panel meeting cancelled?
What are Aditxt's (ADTX) main business focus areas?
